Our management team has extensive experience in pharmaceutical development, particularly in endocrine and cardiovascular therapies, having participated in over 60 clinical development programs in their careers. This team has contributed to over 30 programs involving approved drugs, ten of which reached annual sales in excess of $1 billion and include the world's best selling pharmaceutical product, Lipitor.

Robert Zerbe, M.D., Chief Executive Officer, Founder
	Dr. Zerbe co-founded QuatRx in November 2000 and has served as Chief Executive Officer and President and as a member of our board of directors since inception. Dr. Zerbe has extensive experience in regulatory affairs and global clinical development at Eli Lilly in the United States and the United Kingdom, where he held a variety of research and development positions, including Managing Director, Lilly Research Center U.K., and Vice President of Clinical Investigation and Regulatory Affairs, from 1982 to 1993. He joined Parke-Davis in 1993, becoming Senior Vice President of Worldwide Clinical Research and Development, during which time he oversaw the successful development programs for Lipitor, Neurontin and other key products. He serves on the boards of AP Pharma, Anesiva and Aastrom Bioscience. Dr. Zerbe earned his medical degree at Indiana University in 1975 and did post graduate training in internal medicine, endocrinology and neuroendocrinology at Indiana University and the National Institutes of Mental Health.
Christopher Nicholas, Chief Operating Officer, Founder
	Mr. Nicholas co-founded QuatRx in November 2000 and has served as our Chief Business Officer since inception. Mr. Nicholas has more than 25 years of global pharmaceutical marketing, business development and general management experience at companies such as Bayer, Hoechst/Roussel and Parke- Davis. He joined Parke-Davis in the U.K. in 1980, and was ultimately responsible for the United Kingdom marketing team before moving to the United States headquarters in 1987. As Vice President of Global Marketing at Parke-Davis, he was responsible for several major products, notably the worldwide launch of Lipitor, and he chaired the co-promotion/co-development partnership on Lipitor with Pfizer. He also had responsibility for Parke-Davis business development. He held Vice President and General Manager positions for Parke-Davis in Benelux from April 1997 to April 1999 and Japan from April 1999 to September 2000. Mr. Nicholas received B.Sc. honors degrees in chemistry and business administration and a diploma in industrial studies in chemistry and biology from Loughborough University in 1976.
Stuart Dombey, M.B., F.R.C.P., Chief Scientific and Regulatory Officer, Founder
	Dr. Dombey co-founded QuatRx in November 2000 and has served as our Chief Scientific and Regulatory Officer since inception. Dr. Dombey is a U.K.-trained physician with more than 25 years of experience in the pharmaceutical industry and 13 years of international regulatory experience. He initially worked for Hoechst as Medical Advisor in the United Kingdom and then for Squibb, first as U.K. Medical Director and then transferred to the United States in 1987 as Vice President, Regulatory Liaison. He joined Parke-Davis in the United States in 1990 as Vice President of International Regulatory Affairs, where he had responsibility for all regulatory activities on Parke-Davis products outside the United States and the development and implementation of innovative regulatory strategies for Parke-Davis compounds. Most recently, he was Vice President of R&D in Japan. Dr. Dombey received his M.B. and Ch. B degrees from the University of Liverpool Medical School in 1971.
Gary Onn, Chief Financial Officer
	Mr. Onn has served as our Chief Financial Officer since November 2003. Mr. Onn is a Certified Public Accountant with over 20 years of finance and management experience. From January 2003 to November 2003, Mr. Onn served as a financial consultant to early-stage businesses. From June 2001 to January 2003, he served as the Chief Financial Officer and interim Chief Executive Officer of Aculight Corporation, a laser development company, and from July 2000 to June 2001, he was the Chief Financial Officer of RevX.net, a software developer. In 1994, Mr. Onn joined Heartstream, a publicly traded developer of automatic external defibrillators, where he served in the position of director of finance and later, Chief Financial Officer. In 1990 he joined publicly traded software developer Aldus Corporation as Financial Reporting Manager responsible for external and internal financial reporting from Aldus' domestic, European, and Asia-Pacific operations. Prior to that, Mr. Onn spent nearly seven years as an auditor with the public accounting firm of Ernst & Young, including two years as an audit manager. Mr. Onn received his B.A. in business administration from the University of Washington in 1983.
Risto Lammintausta, M.D., Ph.D., Managing Director, Hormos Medical
	Dr. Lammintausta co-founded Hormos Medical Ltd. in 1997 and has served as its Chief Executive Officer since that time. Mr. Lammintausta joined us in May 2005 in connection with our acquisition of Hormos. Previously, he was Vice President for new drug development at Orion Corporation from 1992 to 1997 and Research Director at Farmos Group Ltd. from 1981 to 1991. In these positions he had responsibility for new compound discovery and development. Dr. Lammintausta served as a member of the Medical Research Council of the Academy of Finland between 1995 and 2000 and is Chairman of the Pharma Cluster Finland. He serves as a member of the board of directors of Juvantia Pharma, Innomedica and the Finnish Cancer Research Foundation. Dr. Lammintausta is a medical doctor and holds a Ph.D. in Pharmacology from the University of Turku.

Learn more about Who We Are by exploring the Management Team and the Board of Directors.